Last $8.78 USD
Change Today +0.17 / 1.97%
Volume 136.9K
RPRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 12:22 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

repros therapeutics inc (RPRX) Snapshot

Open
$8.63
Previous Close
$8.61
Day High
$8.78
Day Low
$8.47
52 Week High
09/2/14 - $22.55
52 Week Low
10/21/14 - $5.92
Market Cap
213.1M
Average Volume 10 Days
348.1K
EPS TTM
$-1.38
Shares Outstanding
24.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REPROS THERAPEUTICS INC (RPRX)

repros therapeutics inc (RPRX) Related Bloomberg News

View More Bloomberg News

repros therapeutics inc (RPRX) Related Businessweek News

No Related Businessweek News Found

repros therapeutics inc (RPRX) Details

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase II clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

28 Employees
Last Reported Date: 11/10/14
Founded in 1987

repros therapeutics inc (RPRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $521.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $275.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $191.3K
Chief Medical Officer
Total Annual Compensation: $181.1K
Vice President of Research & Development
Total Annual Compensation: $183.3K
Compensation as of Fiscal Year 2013.

repros therapeutics inc (RPRX) Key Developments

Repros Initiates Two Phase 2B Uterine Fibroid Studies

Repros Therapeutics Inc. announced it has initiated two Phase 2B efficacy studies of Proellex® in the treatment of uterine fibroids in women that experience heavy vaginal bleeding as a result of these benign tumors. The two studies both have the same FDA suggested endpoints but test two different routes of administration, oral and vaginal. The Company had previously tested both routes using similar doses and found that Proellex® exhibited significant effects on bleeding due to uterine fibroids with each route of administration. In addition to significant effects on bleeding due to Proellex® administration, tumor size was significantly reduced. As a result of reduced tumor burden, bulk symptoms improved to the point where the majority of subjects reported to be symptom free using the Uterine Fibroid Symptom Quality of Life survey (UFSQoL). The UFSQoL is a validated survey that was used to approve uterine artery embolization and ultrasound focusing. In earlier Phase 2 studies, both oral and vaginal administration of Proellex® stopped menses and hence, in this study, on recommendation from the FDA, Repros has chosen amenorrhea as the primary efficacy endpoint. The studies both have three double blind arms: placebo and Proellex® at 6 mg and 12 mg doses. The two studies are powered to achieve the desired impact on menstrual bleeding with only 15 subjects per arm. In addition to investigating the incidence of amenorrhea, actual menstrual blood loss will be estimated by the alkaline hematin method from used sanitary products. The studies are designed to treat women for two 4-month dosing courses separated by an off drug interval to allow for menses. Following the second course, the FDA instructed the Company to follow the women for six additional menstrual events to investigate the duration of benefit. The Company plans to request a Type C meeting after all the subjects have experienced the menstrual event following the first course of treatment. An interim assessment of efficacy and safety is part of the analysis plan. Assuming enrollment proceeds according to plan, the Company believes it can schedule a Type C meeting with the FDA around year end 2015. The purpose of this meeting will be to discuss the overall FDA proposed size of the safety database required for an NDA.

Repros Therapeutics Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Repros Therapeutics Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Repros Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Repros Therapeutics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues and other income was $2,000 against $3,000 a year ago. Net loss was $7,382,000 against $5,998,000 a year ago. Net loss per share - basic and diluted was $0.32 against $0.26 a year ago. For the nine months, the company reported total revenues and other income was $7,000 against $6,000 a year ago. Net loss was $24,634,000 against $20,579,000 a year ago. Net loss per share - basic and diluted was $1.06 against $1.03 a year ago. The increases in net loss for both the three and nine month periods ended September 30, 2014 as compared to the same period in 2013 were primarily due to an increase in expenses related to the clinical development of Androxal, an increase in costs of professional services and increased payroll and benefits expenses due to increased headcount. The decrease for the three month period ended September 30, 2014 as compared to the same period in the prior year was primarily due to a decrease in interest income as a result of decreased cash balances. The increase for the nine month period ended September 30, 2014 as compared to the same period in the prior year was primarily due to an increase in interest income as a result of increased cash balances.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPRX:US $8.78 USD +0.17

RPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPRX.
View Industry Companies
 

Industry Analysis

RPRX

Industry Average

Valuation RPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPROS THERAPEUTICS INC, please visit www.reprosrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.